The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma
{{output}}
Background: Novel agents (NAs) such as thalidomide and bortezomib have been administered in combination with autologous stem-cell transplantation (ASCT) to effectively treat multiple myeloma (MM). However, whether NAs perform bet... ...
